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OBJECTIVE — To assess the long-term cost-effectiveness of aspirin use among adults aged
40 years with newly diagnosed type 2 diabetes.
RESEARCH DESIGN AND METHODS — We used a validated cost-effectiveness
model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of
aspirin. The model simulates the progression of diabetes and accompanying complications for a
cohortofsubjectswithtype2diabetes.Themodelpredictstheoutcomesoftype2diabetesalong
ﬁve disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke)
from the time of diagnosis until age 94 years or until death.
RESULTS — Overalifetime,aspirinusersgained0.31life-years(LY)or0.19quality-adjusted
LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-
effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained.
In probabilistic sensitivity analyses, the ICER was $30,000 per QALY in all of 2,000 realiza-
tions in two scenarios.
CONCLUSIONS — Regular use of aspirin among people with newly diagnosed diabetes is
cost-effective.
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D
iabetes is a major risk factor for car-
diovascular disease (CVD) among
people with diabetes. The risk of
developing coronary heart disease (CHD)
istwotofourtimeshigherforpeoplewith
diabetes than those without diabetes (1).
Aspirin decreases CHD incidence in
adults at risk for CVD (2,3).
The American Diabetes Association
recommends aspirin use for primary pre-
vention of CVD in diabetic patients aged
40yearsorinallpeopleaged30years
if they have risk factors for CVD and no
aspirin contraindications (4). However,
the cost-effectiveness of aspirin use for
primary prevention in a diabetic popu-
lation has not been evaluated. Previous
studies have evaluated the cost-
effectiveness of aspirin therapy for pri-
mary prevention of CVD in the general
population (5,6). These studies con-
cluded that aspirin use was cost saving or
cost-effective. It is not known if the same
conclusion holds for people with diabe-
tes. The cost-effectiveness of aspirin ther-
apy could differ between people with
diabetes and the general population be-
cause of the additional cost and health
consequences related to diabetes and its
complications. Our study evaluates the
lifetimecost-effectivenessofaspirinusein
adults aged 40 years who have newly
diagnosed type 2 diabetes.
RESEARCH DESIGN AND
METHODS— We assessed the cost-
effectiveness of aspirin use by comparing
the long-term health and cost conse-
quences of aspirin use and no aspirin use
among people with newly diagnosed type
2 diabetes under different scenarios, us-
ing a diabetes cost-effectiveness model
developed by the Centers for Disease
Control and Prevention (CDC) and the
Research Triangle Institute (RTI).
The model
Details of the CDC-RTI diabetes cost-
effectiveness model appear elsewhere
(7,8). Brieﬂy, it is a Markov disease pro-
gression model of type 2 diabetes. The
model starts patients at the time of diag-
nosis of their diabetes and progresses
them until death or until age 94 years.
Diabetic patients in the model can de-
velop ﬁve complications: neuropathy,
nephropathy, retinopathy, CHD (i.e.,
cardiac arrest [CA]/myocardial infarc-
tion [MI] and angina), and stroke. Each
complication has its own costs, and the
model aggregates costs over a patient’s
lifetime. Death can result from diabetes
complications or from other causes (7).
Themodelalsosimulatespossiblesideef-
fectsofaspirintherapyongastrointestinal
bleeding. The transitional probabilities
betweenmodeleddiseasestatesandinter-
vention effectiveness parameters were
derived from the Framingham Heart
Study,theUKProspectiveDiabetesStudy
(UKPDS), and other clinical trials and ob-
servational studies (9–11).
The model was validated following
procedures of the American Diabetes As-
sociation Consensus Panel on Computer
Modeling (12). Overall, the diabetes cost-
effectiveness model accurately simulates
the natural history of the diabetic popu-
lation. This model has been used to eval-
uate the cost-effectiveness of many type 2
diabetes interventions (7,8).
We deﬁned the demographics of our
simulatedpopulationasdescribedbelow.
We calculated incidence rates for cohorts
deﬁned through age, sex, and race/
ethnicity using data from the 2005 Na-
tional Health Interview Survey, reported
bytheCDC.Weestimatedtheprevalence
of hypertension, high cholesterol, and
smoking using National Health and Nu-
trition Examination Survey (NHANES)
2001–2006 data. We also obtained the
initial prevalence of diabetes complica-
tions(nephropathy,neuropathy,retinop-
athy, CHD, and stroke) using NHANES
data from 2001 to 2006. The initial A1C
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UKPDS (9,10).
Baseline analysis
We modeled daily use of 80 mg of aspirin
among a cohort of U.S. residents aged
40–94 years who, in 2006, were newly
diagnosed with diabetes. We deﬁned
standard care for subjects with diabetes:
all patients received intensive glucose
control with a treatment intensity similar
to that of the intensive arm of the UKPDS
(A1C 7%); and hypertensive patients
were treated to meet the target diastolic
blood pressure of 80 mmHg, the target
blood pressure rate in the UKPDS
intensive arm. We assessed the cost-
effectiveness of aspirin use plus standard
care compared with standard care alone.
We assumed that aspirin was effective for
everyone who took it. We also assumed
100% compliance. Table 1 shows the
main analytic parameters’ values and the
sources of these parameters.
Health beneﬁts of regular aspirin
usage
A recently published meta-analysis esti-
mated the effect of aspirin use in primary
preventionofCVDinpatientswithdiabe-
tes. The conclusion was that the effect of
aspirin use in patients with diabetes re-
mains unproved (13). We are aware of no
data that suggest that the effect of aspirin
on primary prevention of CVD in the di-
abetic population differs from that in the
generalpopulation.Accordingly,weused
the effects that were derived from a new
meta-analysesofclinicaltrialsforthegen-
eral population in the base-case scenario.
In the base-case analysis, for primary pre-
vention, aspirin use reduced annual risk
of coronary events by 18% and stroke by
5%; for secondary prevention, aspirin re-
duced the risk of major coronary events
by 20% (14).
In our base-case scenario, we as-
sumed that CVD-free patients with newly
diagnosed diabetes received aspirin for
primary CVD prevention. Those with a
history of MI (13%) at the time of diagno-
sisofdiabetesreceivedaspirinforsecond-
ary CVD prevention. In addition, we
assumed that the effects of aspirin use on
primary or secondary prevention in the
trial lasted throughout the lifetime.
Side effects of aspirin use
Aspirin use increases risk of hemorrhagic
strokeandreducesriskofischemicstroke
(14). However, we did not have reliable
cost data for hemorrhagic stroke. Thus,
we used the overall risk ratio (RR) of 0.95
for all stroke events, whether ischemic or
hemorrhagic, in the base-case analysis.
We modeled ischemic and hemorrhagic
strokes separately in the sensitivity analy-
ses, described later. Aspirin use also
increases the risk of gastrointestinal
bleeding. For major gastrointestinal
bleeding, the RR associated with aspirin
use was 1.54. We assumed no gastroin-
testinal bleeding for patients not using
aspirin. We estimated that the gastroin-
testinal bleeding occurred in patients in
the aspirin group at a rate of 0.03 per 100
(14). We assumed that patients who ex-
perienced aspirin side effects would stop
taking aspirin.
Costs
Our analysis, conducted from a health
system perspective, includes only direct
medical costs. We considered the follow-
ing: cost of aspirin treatment, costs of the
standard care (intensive glycemic control
forallpatientsandintensivehypertension
control for patients with hypertension),
costs of treating diabetes complications,
and costs of treating aspirin side effects.
Costsforstandardcareanddiabetescom-
plications were estimated using a multi-
plicative cost function. This cost function
was based on data from adults with dia-
betes under different treatment regimes
and with different complications and co-
morbidities (15,16). We obtained the
costsofaspirinfromWebsitesofthelarge
chain pharmacies and gastrointestinal
bleeding from the literature and added
them to the total costs of treatment for
diabetes and its complications (Table 1)
(5).Wealsoassumedthatgastrointestinal
bleeding occurs only once and incurs
costs only in the ﬁrst year after occur-
rence. All costs were converted to 2006
U.S. dollars by using the Consumer Price
Index for medical services.
Outcomes
Measures of primary outcomes for our
analysis were the number of life-years
(LYs) and the number of quality-adjusted
Table 1—Baseline values and sources of data for selected variables used to estimate the
cost-effectiveness of aspirin use among people with diabetes (costs in 2006 U.S. dollars)
Parameter (reference number) Base-case estimates
Relative risk of primary prevention RR (95% CI)
Major coronary events (14) 0.82 (0.75–0.90)
Overall stroke (14) 0.95 (0.85–1.06)
Hemorrhagic (14) 1.32 (1.00–1.75)
Ischemic (14) 0.86 (0.74–1.00)
Relative risk of secondary prevention
Major coronary events (14) 0.80 (0.73–0.88)
Annual risk for side effects % (95% CI)
Gastrointestinal bleeding (14) 0.0003 (0.0002–0.0005)
Death resulting from gastrointestinal bleeding (18) 0.00001 (0.000001–0.0001)
Annual cost* 0.001 (0.001–0.01)
Aspirin† 24
MI (15)
Year 1 7,765
Ongoing annual cost after year 1 2,006
Stroke (15)
Year 1 67,347
Ongoing annual cost after year 1 26,553
Gastrointestinal bleeding (18)
Nonfatal 7,842
Fatal 7,842
Utility score (17)
Diabetes without complications 0.689
MI 0.637
Stroke 0.617
Gastrointestinal bleeding 0.970
Data are point estimate (95% CI) unless otherwise indicated. *Per person with newly diagnosed type 2
diabetes.†AveragingthepriceofBayerlow-doseaspirin(i.e.,babyaspirin)atseverallargechainpharmacies
in the U.S.
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ical diagnosis of diabetes until the cohort
reaches 94 years of age or death. We used
an additive model for the utility measures
(17). In this model, patients with charac-
teristics (e.g., demographic characteris-
tics, risk factors, complications, and BMI)
differing from the baseline characteristics
had those characteristics’ disutility coefﬁ-
cients added to the intercept (17). For ex-
ample, for a male subjects with BMI 30
kg/m
2 and without major complications,
the state of having diabetes had a utility
value of 0.689. If this subject had a car-
diac arrest/MI, his utility score was re-
duced from the baseline score by 0.052.
We also assumed no disutility for taking
aspirin and a disutility of 0.030 for gas-
trointestinal bleeding (18). Costs and
QALYs were discounted at 3% annually.
Sensitivity analyses
We conducted both one-way and proba-
bilistic sensitivity analyses. For the
former, we considered multiple scenar-
ios. We examined the effectiveness and
cost-effectiveness for several age-groups
and both sexes. We used the upper and
lower 95% conﬁdence bounds of the
main parameters and the parameters in
diabetes subgroups reported by De
Berardis et al. (13). Because the average
follow-up times in the primary and sec-
ondary prevention trials for aspirin use
were 5 and 3 years, respectively, we mod-
eledinterventionswithbeneﬁtslimitedto
the trial follow-up time. We also varied
the cost of gastrointestinal bleeding and
compliance rate and modeled cost-
effectiveness of aspirin use for secondary
prevention of CVD only.
Substantial proportions of diabetic
patients do not receive intensive glycemic
or hypertension control (19). Aspirin use
might be more effective in these patients
because of their increased CVD risk. We
modeled the aspirin cost-effectiveness in
patients with less intensive glucose or
bloodpressurecontrolastheUKPDScon-
trol arms.
We also modeled ischemic and hem-
orrhagic strokes separately. We assumed
that all strokes in the nonaspirin group
wereischemicandmodeledthechangein
costs and effectiveness of aspirin use as a
result of increased risk for hemorrhagic
stroke and decreased risk for ischemic
stroke.Weassumedanexcessannualrisk
of hemorrhagic stroke and decreased risk
of ischemic stroke as reported in the An-
tithrombotic Trialists’ (ATT) Study (14).
The multiplicative cost model did not
provide costs for hemorrhagic stroke. Ac-
cordingly, we calculated that cost by ad-
justing the cost of ischemic stroke, using
the ratios of the ﬁrst year and ongoing
costs between hemorrhagic stroke and
ischemicstrokereportedbyPignoneetal.
(5), respectively. This is equivalent to as-
suming that the cost ratios between hem-
orrhagic and ischemic strokes are
constant as reported in the study by Pig-
none et al.
For our probabilistic sensitivity anal-
ysis, we randomly varied the following
parameters in the model simultaneously
based on distributions of their estimates:
relativeriskofaspirinuseforprimaryand
secondary prevention of CHD, stroke,
and gastrointestinal bleeding; utilities for
all health states; and cost of MI, stroke,
and gastrointestinal bleeding. We as-
sumed that efﬁcacy and the rate of side
effects followed a log-normal distribu-
tion. We assumed a log-normal distribu-
tion for MI and stroke cost, a triangular
distributionforthecostofgastrointestinal
bleeding, and a normal distribution for
utility data with reported means and SDs.
Running simulations for all age-groups
was computationally prohibitive. How-
ever, the baseline effectiveness, cost, and
cost-effectiveness ratios for the 55–64
years age-group were similar to those for
the entire population. Accordingly, we
ran 1,000 realizations using parameters
on the efﬁcacy of aspirin use reported in
the ATT study (14) and the study by De
Berardis et al. (13), limited to the 55–64
years age-group, and reported the results
as our probabilistic sensitivity analysis.
Results for base-case analysis
Over the lifetime of people with newly
diagnosed diabetes, aspirin use reduced
the cumulative incidence of CHD events
by 3.91% and the CHD mortality rate by
4.65%; however, aspirin increased the
cumulative incidence of stroke by 0.51%
and the stroke mortality rate by 0.28%.
Overall, a person in the aspirin group
gained 0.31 LYs and 0.19 QALYs (dis-
countedat3%annually)comparedwitha
person who did not take aspirin, at an
incremental cost of $1,700. The Incre-
mentalcost-effectivenessratio(ICER)was
$5,428 per LY gained or $8,801 per
QALY gained (Table 2).
Results for sensitivity analyses
The one-way sensitivity analysis showed
that the ICERs of aspirin use changed mod-
erately if the extreme values for the effect of
aspirin on primary prevention of CHD, dif-
ferent sex, aspirin effect on secondary pre-
vention, and modeling different types of
strokes separately hold. The ICERs did not
changesubstantiallyforothervariables(Ta-
ble 3). Using the upper 95% of conﬁdence
limitsoftheeffectofaspirininprimarypre-
Table 2—Effectiveness and costs of aspirin treatment
Outcome*
Aspirin
group Nonaspirin group Difference
Cumulative risk of history of
cardiac arrest/MI (%) 33.15 36.15 3.00
Cumulative risk of angina (%) 10.93 12.46 1.53
Cumulative risk of CHD (%) 42.12 46.03 3.91
Cumulative risk of stroke (%) 16.96 16.45 0.51
Cumulative risk of gastrointestinal
bleeding (%) 0.44 0 (only inputs excess risk
of gastrointestinal
bleeding in the model)
0.44
Mortality rate due to CHD (%) 31.15 35.80 4.65
Mortality rate due to stroke (%) 6.93 6.65 0.28
Remaining life years (LYs) 8.67 8.98 0.31
Remaining QALYs 7.34 7.15 0.19
Costs†
Cost of aspirin treatment 278 0 278
Cost for intensive diabetes and
hypertension treatment 39,809 38,398 1,411
Cost for treating complications 31,021 31,010 10
Total costs 71,108 69,407 1,700
*Outcomesoneffectivenessofaspirinwereroundedtothenearest100th.†Unitforcostwas2006USdollars.
Data are point estimates.
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Sensitivity analysis scenario†
Cost-effectiveness ratios
Life year
gained (LYG)‡
QALY
gained‡
Incremental
costs Cost/LYG ($) Cost/QALY ($)
Base-case analysis 0.31 0.19 1,700 5,428 8,801
Age-group when diagnosed with diabetes (years)
35–44 0.37 0.22 1,999 5,415 8,943
45–54 0.38 0.24 2,033 5,283 8,619
55–64 0.35 0.21 1,837 5,311 8,557
65–74 0.26 0.16 1,490 5,762 9,201
75 0.13 0.08 787 6,201 9,890
Sex
Male§ 0.36 0.23 1,329 3,685 5,752
Female§ 0.27 0.16 2,237 8,239 13,833
Effectiveness of aspirin
Primary on CHD (RR 0.82)
95% CI (0.90) 0.25 0.15 1,700 6,894 11,289
95% CI (0.75) 0.37 0.23 1,703 4,555 7,342
Secondary on CHD (RR 0.80)
95% CI (0.88) 0.37 0.23 2,243 5,998 9,796
95% CI (0.73) 0.25 0.16 1,128 4,526 7,258
Side effect
Total stroke (RR 0.95)
95% CI (0.85) 0.31 0.19 1,734 5,590 9,088
95% CI (1.06) 0.30 0.18 1,821 6,032 9,882
Gastrointestinal bleeding (excess risk 0.03%)
95% CI (0.05%) 0.31 0.19 1,714 5,481 8,890
95% CI (0.02%) 0.31 0.19 1,694 5,402 8,757
Diabetes subgroup  0.26 0.16 1,567 6,056 9,783
Men with diabetes  0.55 0.35 1,282 2,344 3,633
Women with diabetes  0.11 0.07 1,492 13,207 22,259
Secondary prevention only 0.16 0.10 1,754 10,841 18,348
Cost of gastrointestinal bleeding ($)
7,800
4,500 0.31 0.19 1,690 5,394 8,746
10,200 0.31 0.19 1,708 5,452 8,840
A1C and blood pressure control goals
Intensive glycemic control  intensive
hypertension control
Standard glycemic control  intensive
hypertension control 0.33 0.20 1,661 5,005 8,240
Intensive glycemic control  standard
hypertension control 0.31 0.19 1,750 5,630 9,203
Standard glycemic control  standard
hypertension control 0.33 0.20 1,718 5,220 8,685
Effectiveness limited in the trial period (aspirin
treatment lifetime) 0.09 0.06 621 6,703 10,669
Effectiveness limited to the trial period (aspirin use
for 5 years) 0.09 0.06 451 4,867 7,746
Compliance rate (%)
100
78 0.24 0.15 1,314 5,420 8,787
56 0.17 0.11 935 5,412 8,773
Modeling ischemic and hemorrhagic stroke separately 0.29 0.18 2,921 9,973 16,484
*Costs, LYGs, and QALYs are discounted at 3% annually; †the bolded text and numbers showed the base-case scenario; ‡rounding to the nearest hundredth;
§parametersarefromATTstudy;RRs:Men:primarypreventionofCHD0.77,ischemicstroke1.01,secondarypreventionofCHD0.81;women:primaryprevention
ofCHD0.95,ischemicstroke0.77,secondarypreventionofCHD0.73. parametersarefromthestudybyDeBerardisetal.RRs:overall:primarypreventionofCHD
0.90, stroke 0.83, secondary prevention of CHD 0.80, gastrointestinal bleeding (excess risk: 0.03%); men: primary prevention of CHD 0.57, stroke 1.11, secondary
prevention of CHD 0.8; women: primary prevention of CHD 1.08, stroke 0.75, secondary prevention of CHD 0.8.
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$8,801/QALY at baseline to $11,289/
QALY. When men and women were mod-
eledseparatelyusingparametersintheATT
study(14)andDeBerardisetal.(13)study,
women always had higher CERs than men:
$13,833/QALY vs. $5,752/QALY using pa-
rameters in ATT study and $22,259/QALY
vs. $3,633/QALY using parameters in De
Berardisetal.study.Onlyconsideringaspi-
rin effect in secondary prevention of CVD
has an ICER of $18,348/QALY. Modeling
hemorrhagic stroke and ischemic stroke
separately yielded an ICER of $16,484/
QALY, which doubled the baseline results.
Figure 1—Results of the probabilistic sensitivity analyses for the cost-effectiveness of aspirin use in newly diagnosed type 2 diabetes. A: Using
parameters for general population in the ATT study. B: Using parameters for diabetes subgroup in the meta-analysis by De Berardis et al. (13). Plot
ofincrementalcostversusincrementalQALYsforaspirinuseversusnoaspirinuse.EachdotonthegraphrepresentsoneICERfromoneofthe1,000
iterations. Solid line represents ICER  $50,000/QALY; dotted line represents ICER  $20,000/QALY. Dots on the right of the lines mean that the
ICERS are less than the ICER the line represents. Dots in quadrant 1 show that the intervention is more effective and less costly; dots in quadrant 4
show that the intervention is cost saving.
Li and Associates
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from the probabilistic sensitivity analysis
of the cost-effectiveness of aspirin using
parametersinthegeneralpopulationasin
the ATT study (14) and parameters in di-
abetes subgroup as in De Berardis et al.
(13) study. Using the ATT study parame-
ters, 100% of the realizations yielded an
ICER of $16,000/QALY gained. The
2.5th and 97.5th percentiles were $5,520
and $12,600 per QALY gained, respec-
tively (Fig. 1A). Using parameters in De
Berardis et al. (13) study, all of the 1,000
simulations yielded an ICER $27,000
per QALY gained. The 2.5th and 97.5th
percentiles were $4,916 and $16,680 per
additional QALY gained, respectively
(Fig. 1B).
CONCLUSIONS — Our study showed
that regular use of aspirin in people with
newly diagnosed type 2 diabetes over
their lifetime cost $8,801 per QALY
gained. Medicare and Medicaid programs
cover many drugs and medical technolo-
gies with much higher ICERs than our
estimatedICERsforaspirin(20).Ifweuse
the conventional $50,000/QALY as the
threshold for cost-effectiveness, aspirin
useisaverycost-effectiveinterventionfor
people with newly diagnosed diabetes.
Bothone-wayandprobabilisticsensitivity
analyses showed that the baseline results
were robust. All the ICERs in one-way
sensitivity analyses were below $25,000/
QALY. There is near certainty that the
ICER of aspirin use for primary preven-
tion is $30,000 per QALY, whether pa-
rameters come from the ATT study or the
De Berardis et al. meta-analysis.
Our study reported higher ICERs of
aspirin use for primary prevention of
CVD in people with diabetes than in
members of the general population who
have a similar risk for CHD or stroke. For
example, Pignone et al. (5) reported that
aspirin use was cost saving in men with a
10-year risk of CHD of 25%; our study
reported an ICER of $5,752/QALY for
men with slightly higher risk of CHD
(28%). For women, Pignone et al. (6) re-
ported an ICER of $2,532/QALY in
womenwitha10-yearstrokeriskof5.5%
and predicted an even lower ICER for
women with higher risk for stroke. In our
study, the ICER was $13,833/QALY for
women with an average 10-year risk of
8.7% for stroke.
Somehavepostulatedthataspirinuse
might be cost saving in people with dia-
betes (21). Our results did not support
this. There are three possible reasons.
First, aspirin’s effect on gastrointestinal
bleeding increased the total medical costs
of the group taking aspirin. Second, the
aspirin treatment group lived longer and
required additional resources for treat-
ment of diabetes and hypertension. Our
study results showed that the treatment
cost for glycemic and hypertension con-
trol was $1,411 higher in the group tak-
ing aspirin than the group not taking
aspirin(Table2).Third,aspirintreatment
affects diabetes macrovascular complica-
tions but not microvascular ones. Those
receiving aspirin therapy live longer due
to reduced risk of CHD and therefore are
more likely to develop diabetic microvas-
cularcomplicationslaterinlife.Wefound
that the cumulative incidence of other di-
abetescomplications(i.e.,end-stagerenal
disease, nephropathy, blindness, and
lower-extremity amputations) at year 10
were similar in both the aspirin and non-
aspirin groups. However, the lifetime cu-
mulativeincidenceofthesecomplications
was higher in the aspirin group, indicat-
ingatotalexcessriskof0.87%inmenand
0.66% in women. However, our results
are consistent with results previously re-
ported by Gaspoz et al. (21) and Kahn et
al.(22)onthecost-effectivenessofaspirin
use in secondary prevention of CVD.
Our study has several limitations.
First, the effectiveness of aspirin use for
people with diabetes needs to be further
demonstrated by large clinical trials. The
difference in the effects of aspirin used as
primary prevention of CVD in people
with and without diabetes is debated
(23). The recently published Prevention
of Progression of Arterial Disease and Di-
abetes Trial in the U.K. and the Japanese
Primary Prevention of Atherosclerosis
With Aspirin for Diabetes trials (24,25)
reported that aspirin did not reduce the
risk of cardiovascular events. However,
questions about aspirin effectiveness re-
main, and two additional trials are under-
way to address the issue of aspirin use
for CVD prevention in people with dia-
betes (14). Our cost-effectiveness anal-
ysis of the aspirin therapy is subject to
change, pending results from ongoing
clinical trials. Second, although our
cost-effectiveness model was validated
against clinical trials, it, like all models, is
based on simplifying assumptions. How-
ever, we have tried to make our as-
sumptions transparent and performed
sensitivity analyses to show the impact of
our assumptions.
Our study shows that regular aspirin
use appears to be very cost-effective in
people aged 40 years with newly diag-
nosed type 2 diabetes. However, use of
aspirin in primary prevention is still con-
troversial.Futureclinicaltrialsareneeded
to better understand if aspirin is efﬁca-
cious for people with type 2 diabetes. Ad-
ditional cost-effectiveness analyses,
accounting for these studies, might be
needed.
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